2024 Dosage Pharmaceutical Manufacturing 
Express Pharma
JANUARY 17, 2025
As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. In March 2024, Lonza hosted its first digital Responsible Supplier Event which brought together more than 1,100 participants.
European Pharmaceutical Review
APRIL 9, 2024
Delpharm has acquired the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas. The 31,600 square meter facility produces some 40 million finished solid dosage forms each year, including tablets, capsules and pellets. billion in 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 12, 2025
The organisation stated, PV (pharmacovigilance) events are generally a reflection of the properties of the active drug substance and the drug product, irrespective of where it is manufactured. Thus, it cannot be conclusively linked with the manufacturing site or manufacturers.
European Pharmaceutical Review
MAY 23, 2024
Benefits in manufacturing The authors illustrated MM-IJ3DP using a novel formulation of a soluble polymer, to enable for the first time, Noyes–Whitney release rates to be programmed and modulated through digital design and manufacture. This paper features in the June 2024 issue of the journal Materials Today Advanced.
Express Pharma
OCTOBER 7, 2024
On October 6, 2024, the Federation of Pharma Entrepreneurs (FOPE) and PharmaState Academy conducted Session 6 of the PULSE (Pharma Upgradation & Learning Series for Excellence) initiative, focusing on HVAC Systems and Qualification in pharmaceutical manufacturing.
Express Pharma
SEPTEMBER 24, 2024
On September 22, 2024, the Federation of Pharma Entrepreneurs (FOPE) and PharmaState Academy hosted Session 5 of the PULSE (Pharma Upgradation and Learning Series for Excellence) initiative, focusing on Water Systems and Qualification. Express Pharma serves as the Media Partner, with Trillyum Consulting as the Knowledge Partner.
FDA Law Blog: Biosimilars
APRIL 16, 2024
Gaulkin — On April 10, the Fourth Circuit unanimously affirmed a summary judgment ruling for the Centers for Medicare & Medicaid Services (CMS) regarding the agency’s definitions of “line-extension drug” and “new formulation” for purposes of determining rebates that drug manufacturers may owe the Medicaid Drug Rebate Program (MDRP).
Expert insights. Personalized for you.
104 
Let's personalize your content